Threshold hypothesis of osteoclast activation

Osteoclast activation is assumed to occur only after passing a putative threshold. Anti-TNF therapy may ideally lead to total inhibition of bioactive TNF. In other patients, anti-TNF therapy may reduce TNF activity below the threshold of osteoclast activation; these patients may continue having sign...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Smolen, Josef S, Aletaha, Daniel, Grisar, Johannes, Redlich, Kurt, Steiner, Günter, Wagner, Oswald
Format: Bild
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Smolen, Josef S
Aletaha, Daniel
Grisar, Johannes
Redlich, Kurt
Steiner, Günter
Wagner, Oswald
description Osteoclast activation is assumed to occur only after passing a putative threshold. Anti-TNF therapy may ideally lead to total inhibition of bioactive TNF. In other patients, anti-TNF therapy may reduce TNF activity below the threshold of osteoclast activation; these patients may continue having signs and symptoms of rheumatoid arthritis. In yet another group of patients, the TNF activity may be reduced, but not to a level that goes below the threshold of osteoclast activation; in these patients, there will be more inflammation than in (c) and some residual destruction – in relation to other therapies, such as methotrexate, the destruction will be significantly less at a similar level of inflammatory signs and symptoms of rheumatoid arthritis [79]. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein.Copyright information:Taken from "The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?"http://arthritis-research.com/content/10/3/208Arthritis Research & Therapy 2008;10(3):208-208.Published online 29 May 2008PMCID:PMC2483438.
doi_str_mv 10.6084/m9.figshare.27791
format Image
fullrecord <record><control><sourceid>datacite_PQ8</sourceid><recordid>TN_cdi_datacite_primary_10_6084_m9_figshare_27791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_6084_m9_figshare_27791</sourcerecordid><originalsourceid>FETCH-datacite_primary_10_6084_m9_figshare_277913</originalsourceid><addsrcrecordid>eNqdzUEKwjAQQNFsXIh6AHe5QGOiYs1aFA_QfRjSaRNITMkMQm8vil7A1V99nhBbo9VJn4-7bNUQRwpQUe3b1pqlaLpQkUJJvQzzVDggRZJlkIUYi09ALMFzfALH8liLxQCJcPPtSpjbtbvcmx4YfGR0U40Z6uyMdm_SZet-pPuQh3-eF59IPpE</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>image</recordtype></control><display><type>image</type><title>Threshold hypothesis of osteoclast activation</title><source>DataCite</source><creator>Smolen, Josef S ; Aletaha, Daniel ; Grisar, Johannes ; Redlich, Kurt ; Steiner, Günter ; Wagner, Oswald</creator><creatorcontrib>Smolen, Josef S ; Aletaha, Daniel ; Grisar, Johannes ; Redlich, Kurt ; Steiner, Günter ; Wagner, Oswald</creatorcontrib><description>Osteoclast activation is assumed to occur only after passing a putative threshold. Anti-TNF therapy may ideally lead to total inhibition of bioactive TNF. In other patients, anti-TNF therapy may reduce TNF activity below the threshold of osteoclast activation; these patients may continue having signs and symptoms of rheumatoid arthritis. In yet another group of patients, the TNF activity may be reduced, but not to a level that goes below the threshold of osteoclast activation; in these patients, there will be more inflammation than in (c) and some residual destruction – in relation to other therapies, such as methotrexate, the destruction will be significantly less at a similar level of inflammatory signs and symptoms of rheumatoid arthritis [79]. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein.Copyright information:Taken from "The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?"http://arthritis-research.com/content/10/3/208Arthritis Research &amp; Therapy 2008;10(3):208-208.Published online 29 May 2008PMCID:PMC2483438.</description><identifier>DOI: 10.6084/m9.figshare.27791</identifier><language>eng</language><publisher>figshare</publisher><subject>Uncategorized</subject><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>781,1895</link.rule.ids><linktorsrc>$$Uhttps://commons.datacite.org/doi.org/10.6084/m9.figshare.27791$$EView_record_in_DataCite.org$$FView_record_in_$$GDataCite.org$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Smolen, Josef S</creatorcontrib><creatorcontrib>Aletaha, Daniel</creatorcontrib><creatorcontrib>Grisar, Johannes</creatorcontrib><creatorcontrib>Redlich, Kurt</creatorcontrib><creatorcontrib>Steiner, Günter</creatorcontrib><creatorcontrib>Wagner, Oswald</creatorcontrib><title>Threshold hypothesis of osteoclast activation</title><description>Osteoclast activation is assumed to occur only after passing a putative threshold. Anti-TNF therapy may ideally lead to total inhibition of bioactive TNF. In other patients, anti-TNF therapy may reduce TNF activity below the threshold of osteoclast activation; these patients may continue having signs and symptoms of rheumatoid arthritis. In yet another group of patients, the TNF activity may be reduced, but not to a level that goes below the threshold of osteoclast activation; in these patients, there will be more inflammation than in (c) and some residual destruction – in relation to other therapies, such as methotrexate, the destruction will be significantly less at a similar level of inflammatory signs and symptoms of rheumatoid arthritis [79]. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein.Copyright information:Taken from "The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?"http://arthritis-research.com/content/10/3/208Arthritis Research &amp; Therapy 2008;10(3):208-208.Published online 29 May 2008PMCID:PMC2483438.</description><subject>Uncategorized</subject><fulltext>true</fulltext><rsrctype>image</rsrctype><creationdate>2011</creationdate><recordtype>image</recordtype><sourceid>PQ8</sourceid><recordid>eNqdzUEKwjAQQNFsXIh6AHe5QGOiYs1aFA_QfRjSaRNITMkMQm8vil7A1V99nhBbo9VJn4-7bNUQRwpQUe3b1pqlaLpQkUJJvQzzVDggRZJlkIUYi09ALMFzfALH8liLxQCJcPPtSpjbtbvcmx4YfGR0U40Z6uyMdm_SZet-pPuQh3-eF59IPpE</recordid><startdate>20111230</startdate><enddate>20111230</enddate><creator>Smolen, Josef S</creator><creator>Aletaha, Daniel</creator><creator>Grisar, Johannes</creator><creator>Redlich, Kurt</creator><creator>Steiner, Günter</creator><creator>Wagner, Oswald</creator><general>figshare</general><scope>DYCCY</scope><scope>PQ8</scope></search><sort><creationdate>20111230</creationdate><title>Threshold hypothesis of osteoclast activation</title><author>Smolen, Josef S ; Aletaha, Daniel ; Grisar, Johannes ; Redlich, Kurt ; Steiner, Günter ; Wagner, Oswald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-datacite_primary_10_6084_m9_figshare_277913</frbrgroupid><rsrctype>images</rsrctype><prefilter>images</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Uncategorized</topic><toplevel>online_resources</toplevel><creatorcontrib>Smolen, Josef S</creatorcontrib><creatorcontrib>Aletaha, Daniel</creatorcontrib><creatorcontrib>Grisar, Johannes</creatorcontrib><creatorcontrib>Redlich, Kurt</creatorcontrib><creatorcontrib>Steiner, Günter</creatorcontrib><creatorcontrib>Wagner, Oswald</creatorcontrib><collection>DataCite (Open Access)</collection><collection>DataCite</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Smolen, Josef S</au><au>Aletaha, Daniel</au><au>Grisar, Johannes</au><au>Redlich, Kurt</au><au>Steiner, Günter</au><au>Wagner, Oswald</au><format>book</format><genre>unknown</genre><ristype>GEN</ristype><title>Threshold hypothesis of osteoclast activation</title><date>2011-12-30</date><risdate>2011</risdate><abstract>Osteoclast activation is assumed to occur only after passing a putative threshold. Anti-TNF therapy may ideally lead to total inhibition of bioactive TNF. In other patients, anti-TNF therapy may reduce TNF activity below the threshold of osteoclast activation; these patients may continue having signs and symptoms of rheumatoid arthritis. In yet another group of patients, the TNF activity may be reduced, but not to a level that goes below the threshold of osteoclast activation; in these patients, there will be more inflammation than in (c) and some residual destruction – in relation to other therapies, such as methotrexate, the destruction will be significantly less at a similar level of inflammatory signs and symptoms of rheumatoid arthritis [79]. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein.Copyright information:Taken from "The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?"http://arthritis-research.com/content/10/3/208Arthritis Research &amp; Therapy 2008;10(3):208-208.Published online 29 May 2008PMCID:PMC2483438.</abstract><pub>figshare</pub><doi>10.6084/m9.figshare.27791</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier DOI: 10.6084/m9.figshare.27791
ispartof
issn
language eng
recordid cdi_datacite_primary_10_6084_m9_figshare_27791
source DataCite
subjects Uncategorized
title Threshold hypothesis of osteoclast activation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T21%3A38%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-datacite_PQ8&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.au=Smolen,%20Josef%20S&rft.date=2011-12-30&rft_id=info:doi/10.6084/m9.figshare.27791&rft_dat=%3Cdatacite_PQ8%3E10_6084_m9_figshare_27791%3C/datacite_PQ8%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true